Globus Medical, Inc. (GMED) Stock Analysis
Healthcare · Medical Devices
Sell if holding. At $89.58, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 2.6): -1.5; Thin upside margin: 7.6%.
Globus Medical is a medical device company developing musculoskeletal solutions and enabling technologies, operating across 65 countries following the 2023 NuVasive and 2025 Nevro mergers. Products are sold through direct and distributor sales representatives to hospitals and... Read more
Sell if holding. At $89.58, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 2.6): -1.5; Thin upside margin: 7.6%. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Score 6.5/10, moderate confidence.
Passes 4/7 gates (clean insider activity, no SEC red flags, news events none recent, semi cycle peak clear). Fails on weak momentum and favorable risk/reward ratio and earnings proximity 7d<=7d. Suitability: moderate.
Thesis
Key Metrics
Quality Signals
Options Flow
Concentration Risks(10-K Item 1A)
- MEDIUMSupplierlimited number of suppliers10-K Item 1A: 'Our dependence on such a limited number of suppliers exposes us to risks, including limited control over pricing, availability, quality and delivery schedules.'
Material Events(8-K, last 90d)
- 2026-03-23Item 5.02LOWJohn A. DeFord, Ph.D. resigned from Globus Medical Board of Directors effective March 23, 2026. Decision not a result of any disagreement with the Company. No successor named for his board seat.SEC filing →
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 floor-breaker·1 ceiling hit
Momentum below the gate floor. Component breakdown shows what dragged the score down.static
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Sell if holding. At $89.58, A.R:R 1.2:1 is below the 1.5:1 minimum. Reward from here is too thin for a buy — the engine flags exit. Additional concerns: Leverage penalty (D/E 2.6): -1.5; Thin upside margin: 7.6%. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Prior stop was $83.61. Score 6.5/10, moderate confidence.
Take-profit target: $96.25 (+7.6% upside). Prior stop was $83.61. Stop-loss: $83.61.
Thin upside margin: 7.6%; Leverage penalty (D/E 2.6): -1.5; Earnings in 7 days (event risk).
Globus Medical, Inc. trades at a P/E of 22.4 (forward 17.7). TrendMatrix value score: 6.9/10. Verdict: Sell.
22 analysts cover GMED with a consensus score of 3.9/5. Average price target: $111.
What does Globus Medical, Inc. do?Globus Medical is a medical device company developing musculoskeletal solutions and enabling technologies, operating...
Globus Medical is a medical device company developing musculoskeletal solutions and enabling technologies, operating across 65 countries following the 2023 NuVasive and 2025 Nevro mergers. Products are sold through direct and distributor sales representatives to hospitals and surgeons; ~80.6% of sales are from the U.S. market.